Matthew J. Hart, Ph.D.
Director, Center for Innovative Drug Discovery High Throughput Screening Facility
Director, Greehey CCRI RNAi/CRISPR Screening Facility
Matthew J. Hart, Ph.D., is an Associate Professor/Research in the Department of Biochemistry and Structural Biology at UT Health San Antonio. Dr. Hart received his doctoral degree from Cornell University and did his postdoctoral training at Onyx Pharmaceuticals. His work identified CDC42 as a regulator of cell growth control, established the role of CDC42 in the regulation of EGFR and the Dbl oncogene, the involvement of p115-RhoGEF in heterotrimeric G-protein signaling, and identified β-TrCP and Axin as a regulator of ß-catenin signaling. Building on 20 years of experience in basic research and in drug discovery (both in pharmaceutical and academic settings), he has led teams in HTS drug discovery programs targeting critical mechanisms of cancer, vascular inflammation, and neurodegenerative diseases. He applies cutting-edge technologies to HTS/rational design approaches to drug discovery and target identification.
Dr. Hart joined the Greehey Children’s Cancer Research Institute (Greehey CCRI) as Director of the Greehey CCRI RNAi/CRISPR High Throughput Screening Facility. Under his direction, the Greehey CCRI RNAi/CRISPR HTS Facility identifies novel mediators of biological pathways of disease that can subsequently be targeted with small molecules. His focus as leader of the Greehey CCRI RNAi/CRISPR High Throughput Screening Facility is to use genetic tools to identify targets and signaling events that play a role in pediatric cancer. Dr. Hart is also the Director of the Center for Innovative Drug Discovery Small Molecule High Throughput Screening Facility and coordinates drug discovery programs with the CIDD Medicinal Chemistry core located at our sister institution UT San Antonio. Under his direction, these facilities work with researchers in South Texas to translate their insights on fundamental mechanisms of a diverse array of human diseases into effective therapeutics or to interrogate cellular signaling pathways to develop novel research directions.
- 1995 - Postdoctoral Training - Biochemistry - Onyx Pharmaceuticals
- 1993 - Postdoctoral Training - Biochemistry - Cornell University
- 1993 - PhD - Biochemistry and Molecular Biology - Cornell University
- 1984 - BA - Biochemistry (Cum Laude) - University of Connecticut
- 2019-present - Director, NCI UT Health San Antonio, Anderson Cancer Center, Drug Discovery and Structural Biology Shared Resource - University of Texas Health San Antonio, MD Anderson Cancer Center
- 2016-present - Director, siRNA/CRISPR Screening Facility - University of Texas Health San Antonio, Greehey Children’s Cancer Research Institute
- 2012 – present - Director, Center for Innovative Drug,Discovery (CIDD) High Throughput, Screening Facility - University of Texas Health San Antonio
- 2016 – present - Associate Professor / Research - University of Texas Health San Antonio, Department of Biochemistry
- 2011- 2016 - Assistant Professor / Research - University of Texas Health San Antonio,Department of Biochemistry
- 2009-2011 - Research Instructor - University of Texas Health San Antonio, Department of Molecular Medicine
- 2007-2009 - Research Instructor - Buck Institute for Age Research, Novato, California
- 2005-2007 - Visiting Scientist - University of California, San Francisco, Comprehensive Cancer Center, Cancer Research Institute
- 2003-2005 - Staff Scientist - Stanford University, Department of Cardiovascular Medicine
- 1999-2003 - Senior Scientist II, Project Team Leader - Millennium Pharmaceuticals, South San Francisco, California
- 1997-1999 Scientist, Onyx Pharmaceuticals, Richmond, CA - Scientist - Onyx Pharmaceuticals
- 1995-1997 - Associate Scientist - Onyx Pharmaceuticals
- 1993-1995 - Postdoctoral Fellow - Onyx Pharmaceuticals
- 1993 - Postdoctoral Fellow - Cornell University
Research & Grants
Dr. Hart has extensive knowledge of high-throughput screening through his experience of many steps in the drug discovery process, including assay development, optimization, and automation. He has many years of experience running HTS in the biotechnology industry, having lead screens successfully using 500,000 compound libraries to identify kinase inhibitors, protease cleavage inhibitors, and others. In addition, Dr. Hart has a strong background in cancer signaling pathways, having made significant contributions to the field of GTPase regulation and beta-catenin biology.